Full-Time

Senior Mechanical Engineer

Mytos

Mytos

11-50 employees

Automated scalable human cell manufacturing platform

No salary listed

London, UK

In Person

Must work from the lab in London; remote work not supported.

Category
Mechanical Engineering (2)
,
Required Skills
Injection Molding
Arduino
Requirements
  • You’ve brought at least one complex product to market - ideally in the lab automation, medical devices or biotech space, but we’re open to other areas too.
  • You have a keen understanding of building reliability into hardware research and development processes.
  • Complex systems containing hardware, electronics and software fascinate you.
  • The open-source hardware movement interests you, even though your industrial experience may not have touched on things like Adafruit, SparkFun, Arduino and Raspberry Pi. What you do enjoy are non-traditional approaches to prototyping and finding ways to get things working. You might even have learnt to code to get things talking to each other.
  • Manufacturing techniques including injection molding, sheet metal fabrication and CNC machining are part of your toolkit.
Responsibilities
  • Make our devices more indestructible - iterate and improve the robustness and reliability of our machines.
  • Lead development of systems that interface to areas you might not be familiar with, such as optics and fluidics.
  • Work on all aspects of hardware design - from initial concept through to manufacture.
  • Refine and build existing proof-of-concept features and collaborate on integrating new ones.
  • Refine our test rigs, quality processes and data, and harness them to improve our sprint velocity and help us move faster.
  • Help shape our engineering culture and processes so that we keep continually improving. You’ll enjoy the autonomy, accountability and customer-focus that we bring to our work.
Desired Qualifications
  • None

Mytos.bio provides automated, end-to-end manufacturing for human cell types used in biotech. It sells and supports its proprietary Mytos Platform, which combines robotics and software to run cell culture processes without needing more staff. This turns traditional artisanal cell culture into scalable, repeatable production for large biotech firms working on cell therapies and drug development. The system works by integrating automated equipment and software workflows that manage culture, monitoring, and quality control, enabling consistent, high-quality cells at scale. Compared with competitors, Mytos.bio emphasizes a turnkey, scalable infrastructure that reduces headcount while delivering uniform results, backed by a team of hardware and software engineers and biologists, and recognition as a YCombinator alumnus and Forbes 30 Under 30. Its goal is to make large-scale cell production reliable and cost-effective so biopharma companies can accelerate therapies and drug development.

Company Size

11-50

Company Stage

Series A

Total Funding

$20.9M

Headquarters

London, United Kingdom

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • $19M Series A from Buckley Ventures accelerates iDEM platform growth.
  • Partnerships with StemSight, Rinri, Novadip scale cell therapies for trials.
  • Aspen Neuroscience collaboration produces DANPCs for Parkinson's ANPD001.

What critics are saying

  • Aspen ANPD001 trial failure terminates Mytos contract, cuts payments.
  • Lonza Cocoon captures 40% market with GMP compliance over iDEM.
  • UK AI Act audits iDEM software, delays deployments, raises costs 30%.

What makes Mytos unique

  • Mytos' iDEM platform fully automates stem cell differentiation to specific human cell types.
  • iDEM integrates fluidics, imaging, and robotics for hands-off, scalable cell production.
  • Y Combinator alumnus Mytos targets biotech firms with precision cell manufacturing.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Mytos who can refer or advise you

Benefits

Stock Options

Pension

Lunch covered daily

24 days holiday (excluding bank holidays)

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Yahoo Finance
Sep 3rd, 2025
Mytos Announces Strategic Partnerships with StemSight, Rinri Therapeutics, and Novadip to Power Next-Generation Cell Therapy Trials

Mytos announces strategic partnerships with StemSight, Rinri Therapeutics, and Novadip to power next-generation cell therapy trials.

Silicon Canals
Jan 8th, 2025
Mytos Announces Manufacturing Collaboration With Aspen Neuroscience In Parkinson'S Disease

Mytos’ automated cell culture technology will power manufacturing of dopaminergic neuronal precursor cells for Aspen’s investigational cell therapy ANPD001 in Parkinson’s diseaseLONDON–(BUSINESS WIRE)–#automation—Mytos, an innovative leader in automated cell manufacturing, has entered into a manufacturing collaboration with Aspen Neuroscience, Inc. to automate the manufacturing of autologous dopaminergic neuronal precursor cells (DANPCs) for ANPD001, Aspen’s investigational cell therapy program for Parkinson’s disease (PD).The DANPCs, designed to replace lost dopamine-producing neurons in the brain, are differentiated from induced pluripotent stem cells (iPSCs), which are derived from the patient’s own skin cells. This approach holds the promise of restoring lost function without the need for immunosuppressive drugs.As part of the partnership agreement, Aspen will integrate Mytos’ iDEM automated cell culture technology into its new manufacturing facility in Torrey Pines, Calif. The iDEM automated cell culture technology combines fluidics, advanced imaging, and mechanical movement and control to enable fully hands-off production of specific human cell types. This agreement represents the potential for substantial payments to Mytos over the coming years.Mytos’ automation has the potential to drive substantial improvements in efficiency and scalability. By closing and automating processes, iDEM empowers operators to manage more batches simultaneously within a smaller cleanroom footprint, minimizing the need for extensive hiring, training, and facility expansions as manufacturing scales out.“We are excited to work with the innovative Mytos team

PitchBook
Dec 1st, 2023
Global VC deals for December 1, 2023

Generative AI business automation startup Kognitos raised a $20 million Series A led by Khosla Ventures.

The Manchester Times
Nov 30th, 2023
Mytos Announces $19M Series A Funding to Automate Human Cell Manufacturing and Further Accelerate Growth

Mytos, an innovative leader in automated cell manufacturing, announced today it has closed $19M in Series A financing led by Buckley Ventures, with participation from IQ Capital and Wing VC.

Securities and Exchange Commission
Oct 12th, 2023
SEC FORM D

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.